



## June 2022 Pharmacy & Therapeutics Committee Decisions

UCare’s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare formularies (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for the Medicare formularies are tentative until UCare receives final CMS approval.

**Key:**

Medicare: UCare Medicare, UCare Medicare with Fairview and North Memorial, UCare Group Medicare, EssentiaCare, Minnesota Senior Health Options (MSHO) & Connect + Medicare

Medicaid: PMAP, MnCare, MSC+ & Connect

Exchange: UCare Individual and Family Plans

F: Formulary

NF: Non-formulary

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

New Drug Review			
Drug	Indication	Formulary Coverage	Effective Date
<b>Vabysmo (faricimab-svoa)</b>	Neovascular (wet) age-related macular degeneration (nAMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary *Covered under medical benefit with PA	N/A
<b>Carvykti (ciltacabtagene autoleucel) PROTECTED CLASS</b>	Carvykti, B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy, is indicated for the treatment of adults with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary  *Covered under medical benefit with PA	N/A
<b>Ibsrela (tenapanor)</b>	Ibsrela, a sodium/hydrogen exchanger 3 (NHE3) inhibitor, is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in patients ≥ 18 years of age.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A

## June 2022 Pharmacy & Therapeutics Committee Decisions

<b>Kimmtrak (tebentafusp-tebn) PROTECTED CLASS</b>	HLA-A*02:01 positive adults with unresectable or metastatic uveal melanoma.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary  *Covered under medical benefit with PA	N/A
<b>Recorlev (levoketoconazole)</b>	Treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
<b>Vonjo (pacritinib citrate) PROTECTED CLASS</b>	treatment of intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis in adults w/ a platelet count < 50 x 10 <sup>9</sup> /L	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	7/1/2022
<b>Pyrukynd (mitapivat sulfate)</b>	The treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
<b>Tezspire (Tezepelumab-ekko)</b>	add-on maintenance treatment of severe asthma in patients 12 years and older	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary *Covered under medical benefit with PA	N/A
<b>Enjaymo (sutimlimb-jome)</b>	decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
<b>Adbry (tralokinumab-ldrm)</b>	the treatment of moderate to severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are	Medicare: Formulary w/PA Medicaid: Non-Formulary Exchange: Non-Formulary	7/1/2022
<b>Cibinqo (abrocitinib)</b>	treatment of refractory, moderate to severe atopic dermatitis in adults whose disease is not adequately controlled with other systemic	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A

## June 2022 Pharmacy & Therapeutics Committee Decisions

	drug products (including biologics) or when those therapies are not advisable.		
--	--	--	--

**Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 6/1/2022.**

### New Indications Review

Drug	Current formulary status	Recommendation
Rinvoq – UC, Ankylosing Spondylitis	Medicare - F, Medicaid - NP, HIX - F	Medicare - F, Medicaid - NP, HIX - F
Lynparza – early breast cancer	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Fintepla-Lennox-Gastaut	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Triumeq – HIV peds 10-40kg	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Lupron Depot – prostate cancer	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Veklury – peds 28d-12yrs	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Cabenuva – peds 12	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Edurant – peds 12+	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
ArmonAir – peds older than 4yrs	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Qelbree - ADHD	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Keytruda – endometrial carcinoma	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Actemera – giant B-cell arteritis	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Yescarta – large B-cell lymphoma	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Ultomiris – myasthenia gravis	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF

### New Generics Review

Drug	Current formulary status	Recommendation
Lacosamide (Vimpat) tablet	Medicare - F, Medicaid - NP, HIX - F	Medicare - F, Medicaid - NF, HIX - F
Brimonidine-timolol (Combigan) eye drops	Medicare - F, Medicaid - P, HIX - F	Medicare - F, Medicaid - NF, HIX - F
Tolvaptan (Samsca) tablet	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - F, Medicaid - NF, HIX - NF

## June 2022 Pharmacy & Therapeutics Committee Decisions

Lacosamide (Vimpat) Vial	Medicare - NF, Medicaid - NP, HIX - F	Medicare - NF, Medicaid - NF, HIX - NF
-----------------------------	---------------------------------------	--

### Miscellaneous Previously Reviewed Items

Drug	Rationale/Alternative	Recommendation
Seglentis (tramadol/celecoxib) tablet	Celecoxib, tramadol	NF all lines of business
Zimhi (naloxone) syringe	Provide all reasonable naloxone options	F all lines of business
Baclofen solution	Baclofen tablets	NF all lines of business
Prehevbrio (Hep B vaccine)	Cover all vaccines	F all lines of business
Citalopram 30mg capsule	Standard citalopram strengths, tablets	NF all lines of business
Nexiclon XR (clonidine tablet)	Clonidine ER, clonidine patch	NF all lines of business
Soanz (torsemide tablet)	Torsemide, furosemide, bumetanide	NF all lines of business
Twynéo (tretinoin/BP cream)	Tretinoin, clinda-tretinoin, benzoyl peroxide, adapalene	NF all lines of business
Releuko (filgrastim)	Zarxio	NF all lines of business
Fleqsuvy 9baclofen suspension)	Baclofen tablets	NF all lines of business

### Additional Items Reviewed

Item	Action
Omnipod 5 Review	<ul style="list-style-type: none"> <li>Adding Omnipod 5 to all formularies</li> </ul>